307 |
Osenga |
A Phase I Clinical Trial of Hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: A Study of the Children's Oncology Group |
308 |
Cheung |
Validation of Cyclin D1, a Gene Identified by Genome-Wide Expression Arrays, as a Marker of Minimal Residual Disease in Neuroblastoma |
309 |
Sano |
Neuroblastoma with Discordant Genotype-Phenotype Relationship of MYCN Amplification and Favorable Histology: A Childrens Oncology Group Study |
310 |
Schmidt |
Parental Report of Late Effects among Long-Term Survivors of Neuroblastoma |
311 |
Messina |
Evaluation of Semi-Quantitative Scoring System for Metaiodobenzylguanidine (mIBG) Scans in Patients with Relapsed Neuroblastoma |
312 |
Maris |
Phase 1 Trial of the Orally Bioavailable Trk Tyrosine Kinase Inhibitor CEP-701 in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Study |
313 |
Ladenstein |
Prophylactic Randomized Use of Granulocyte Colony-Stimulating Factor (G-CSF/Filgrastim) during the Rapid Cojec Induction Phase of the European High Risk Neuroblastoma (HR-NBL-1/ESIOP) Study |
314 |
Simon |
Intensified External Beam Radiation Therapy Improves the Outcome of Stage 4 Neuroblastoma in Children >1 Year with Residual Local Disease |
315 |
Jenkner |
Topotecan and High Dose Cyclophosphamide Followed by Ifosfamide, Carboplatin and Etoposide in Newly Diagnosed High Risk Neuroblastoma |
316 |
Park |
Targeted Topotecan during Induction Therapy of High Risk Neuroblastoma: A COG Pilot Study |
317 |
Simon |
The Combination of Topotecan, Cyclophosphamide, and Etoposide Is Effective in the Treatment of Neuroblastoma. Results of a Phase II Trial |
318 |
Rubie |
Temozolomide Phase II Study in Children with Relapsing/Refractory High-Risk Neuroblastoma |
319 |
Kushner |
Five-Day Courses of Irinotecan-Temozolomide for Relapsed or Refractory Neuroblastoma (NB) |
320 |
Schroeder |
Prediction of Target CD34 Positive Cells Following Leukopheresis in Children with Neuroblastoma |
321 |
Modak |
Feasibility of Peripheral Blood Hematopoietic Stem Cell Harvest after Three or More Cycles of Dose-Intensive Chemotherapy for Stage 4 Neuroblastoma |
322 |
Yamashiro |
Feasibility of Autologous Stem Cell Transplant Followed by Reduced Intensity Allogeneic Stem Cell Transplantion as Consolidation for High Risk Neuroblastoma: A Single Institution Pilot Study |
323 |
Sakata |
Feasibility and Efficacy of HLA-Haploidentical Stem Cell Transplantation for the Treatment of High-Risk Advanced Neuroblastoma |
324 |
Kogner |
Pharmacokinetics of Celecoxib in Pediatric Cancer Patients after Oral Administration |
325 |
Lode |
Preclinical Efficacy and Clinical Toxicity Profile of New ch14.18 Antibody Produced in CHO Cells |
326 |
Modak |
Combination of Anti-GD2 Antibody 3F8 and Barley-Derived (1→3), 1→4) Β-D-Glucan: Phase I Study in Patients with Resistant Neuroblastoma |
327 |
Chan |
Treatment Outcome of Metastatic Neuroblastoma with Antiganglioside 2 Monoclonal Antibody (3F8): The Hong Kong Experience |
328 |
Lin |
Pre-Administration of Heat-Modified 3F8 (HM3F8) Reduces 3F8 Infusion-Associated Pain In Patients with Neuroblastoma (NB) |
329 |
Niezgoda |
Central Nervous System Relapses in Children over 1 Year of Age with 4 Stage Neuroblastoma |
330 |
Kramer |
Metastatic Central Nervous System Neuroblastoma: Improved Outcome with Intrathecal Radioimmunotherapy |
331 |
Gigliotti |
Neuroblastoma in the Newborn. The Italian Experience with 115 Cases |
332 |
Yoneda |
Clinical Dilemma of Prognostic Evaluation on MYCN Amplification in Infantile Neuroblastomas |
333 |
Podda |
Stage 3 Neuroblastoma over the Age of One: Experience of the Istituto Nazionale Tumori of Milan with a Treatment Program Including Sequential Hemibody Irradiation as Consolidation Treatment |
334 |
Marachelian |
Prognostic Impact and Pathologic Correlation of Residual Tumor in Intermediate Risk Stage 3 Neuroblastoma |
335 |
Baker |
The Prognostic Impact of Unfavourable Metastatic Sites at Diagnosis in Intermediate Risk Neuroblastoma An Interim Analysis of Children's Oncology Group Protocol A3961 |
336 |
Hero |
The Different Nature of Relapses in Stage 4S without MYCN Amplification: Transition to Stage 4 vs. Maturing Relapses with Good Prognosis |
337 |
Shulkin |
Metabolic Characterization of Neuroblastoma |
338 |
Shulkin |
Effects of Commonly Prescribed Drugs on MIBG Uptake In Vitro |
339 |
Tanaka |
Risk Predictors and Biological Discrimination in Advanced Neuroblastomas during Last Three Decades in Japan |
340 |
Pawel |
Development and Validation of a Neuroblastoma Tissue Microarray |
341 |
Swerts |
DRAQ5: Improved Multiparameter Flow Cytometric DNA Content Analysis in Neuroblastoma |
342 |
Cheung |
Molecular Detection of Metastatic Neuroblastoma in Bone Marrow Samples: A Comparison of Sampling by Ficoll-Separated Mononuclear Cells Versus Whole Marrow |
343 |
Corrias |
PBSC Tumor Cell Contamination by Quantitative RT-PCR for Tyrosine Hydroxylase and GD2 Synthase and Survival of Neuroblastoma Patients |
344 |
Burchill |
European Standard Operating Procedures for the Collection, Processing, Analysis and Reporting of Minimal Disease by Real-Time Reverse Transcriptase-Polymerase Chain Reaction; a SIOPEN-R-NET Project |
345 |
Swerts |
ELAVL4: A New Molecular Marker for Detection of Disseminated Neuroblastoma Cells Using Real-Time Quantitative RT-PCR |
346 |
Oltra |
Utility of the Doublecortin Gene as a New Molecular Marker To Detect Minimal Residual Disease in Neuroblastoma |
347 |
Russell |
Prolonged Survival for Patients with Refractory Neuroblastoma |
348 |
Kushner |
Secondary Leukemia (SL)/Myelodysplasia (MDS) and Bone Marrow (BM) Cytogenetic Aberrations after Dose-Intensive Chemotherapy for Neuroblastoma (NB) |
349 |
Angelini |
Late Sequelae of Spinal Cord Compression (SCC) in Children with Neuroblastoma |
350 |
Tersak |
Rituximab (Anti-CD20) in the Treatment of Four Patients with Refractory Neuroblastoma Associated Opsoclonus-Myoclonus |
351 |
Ash |
Paraneoplastic Limbic Encephalitis Accompanying Nodular Ganglioneuroblastoma Therapeutic Dilemma |
352 |
Iehara |
The Results from the Comparison between Clinical Feature of Mass Screening and That of Non-Mass Screening in Infant Neuroblastoma |
353 |
Hayashi |
Neuroblastoma Mortality in Screened and Unscreened Children: A Meta-Analysis of Population-Based Studies of HPLC Mass-Screening |
354 |
London |
Lower Incidence of Neuroblastoma in Hispanic Populations |
355 |
Kurkure |
Clinico Biological Profile and Challenges in the Management of Non-Infantile High Risk Neuroblastoma at Tata Memorial Hospital in India |
356 |
Balwierz |
Pathological Evaluation of Retroperitoneal Lymph Nodes after Intensive Chemotherapy in Children with Stage 4 Neuroblastoma over 1 Year of Age |
357 |
Zhang |
Abdominal Tumours in Children: 3-D Visualisation and Surgical Planning |
358 |
Malis |
Successful Multiple Surgery in the Treatment of Multifocal Pheochromocytoma in a 13 yrs Old Girl |
